SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Liubao Peng · Study

Home/Author

Liubao Peng

4 works· latest 2019· 2 institutionscluster: provisionalORCID 0000-0001-6155-0709

h-index4

i104

Citations352

Works here4

15

19

Most cited in this library

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma2019 · 150 citations
First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis2019 · 105 citations
A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study2015 · 49 citations
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis2019 · 48 citations

Works

4 shown

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

Clinical Drug Investigation·2019·7 authors·Open access

48citations

First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis

Cancer·2019·6 authors·Open access

105citations

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma

JAMA Oncology·2019·5 authors·Open access

150citations

A Review and Comparison of Methods for Recreating Individual Patient Data from Published Kaplan-Meier Survival Curves for Economic Evaluations: A Simulation Study

PLoS ONE·2015·3 authors·Open access

49citations